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Abstract
Objective. Evaluation of the efficacy of green tea extract (GTE) in regulating chemokine production and
chemokine receptor expression in human RA synovial fibroblasts and rat adjuvant-induced arthritis (AIA).
Methods. Fibroblasts isolated from human RA synovium were used in the study. Regulated upon
activation normal T cell expressed and secreted (RANTES)/CCL5, monocyte chemoattractant protein
(MCP)-1/CCL2, growth-regulated oncogene (GRO)a/CXCL1 and IL-8/CXCL8 production was measured
by ELISA. Western blotting was used to study the phosphorylation of protein kinase C (PKC)d and
c-Jun N-terminal kinases (JNK). Chemokine and chemokine receptor expression was determined by
quantitative RT–PCR. The benefit of GTE administration in rat AIA was determined.
Results. GTE (2.5–40mg/ml) inhibited IL-1b-induced MCP-1/CCL2 (10 ng/ml), RANTES/CCL5,
GROa/CXCL1 and IL-8/CXCL8 production in human RA synovial fibroblasts (P< 0.05). However, GTE
inhibited MCP-1/CCL2 and GROa/CXCL1 mRNA synthesis in RA synovial fibroblasts. Furthermore, GTE
also inhibited IL-1b-induced phosphorylation of PKCd, the signalling pathway mediating IL-1b-induced
chemokine production. Interestingly, GTE preincubation enhanced constitutive and IL-1b-induced CCR1,
CCR2b, CCR5, CXCR1 and CXCR2 receptor expression. GTE administration (200 mg/kg/day p.o.) mod-
estly ameliorated rat AIA, which was accompanied by a decrease in MCP-1/CCL2 and GROa/CXCL1
levels and enhanced CCR-1, -2, -5 and CXCR1 receptor expression in the joints of GTE administered rats.
Conclusions. Chemokine receptor overexpression with reduced chemokine production by GTE may be
one potential mechanism to limit the overall inflammation and joint destruction in RA.
Key words: Green tea, Chemokines, Chemokine receptors, Rheumatoid arthritis, Synovial fibroblasts,
Complementary and alternative medicine, Adjuvant-induced arthritis.
Introduction
RA is a chronic inflammatory disease leading to joint
destruction mediated in part by the migration of inflamma-
tory cells into the synovial tissue [1]. In response to the
pro-inflammatory cytokines produced by macrophages,
such as IL-1b and TNF-a, RA synovial fibroblasts produce
chemokines that promote inflammation and neovascular-
ization in the arthritic joint [1]. Although cytokine-specific
biological agents have improved the treatment of RA, still
in clinical practice, patients only respond partially to such
therapies [2–4]. Thus, in order to achieve additional
improvements in RA therapy, newer treatment combi-
nations need to be tested.
Chemokines are a specialized family of small (8–
10-kDa), structurally related proteins classified into four
supergene families, C, CC, CXC and CX3C, based on
the position of N-terminal cysteine residues [5]. CC and
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CXC chemokines are well-established regulators of gene
transcription, cell proliferation and leucocyte trafficking to
normal and inflamed tissues [6, 7]. Chemokines such as
monocyte chemoattractant protein 1 (MCP-1)/CCL2,
regulated upon activation normal T cell expressed and
secreted (RANTES)/CCL5, growth-regulated oncogene a
(GROa)/CXCL1 and IL-8/CXCL8 are potent chemotactic
agents that are constitutively produced by RA synovial
fibroblasts and further up-regulated upon cytokine stimu-
lation [8]. The inhibition of chemokine–chemokine receptor
interaction has shown promise in animal models of arthri-
tis [9, 10]. Primarily, chemokines have been associated
with the regulation of leucocyte trafficking to normal and
inflamed tissues [11, 12]. However, in addition to leuco-
cytes, the other non-haematopoietic cell types, including
endothelial cells, fibroblasts and several tumour lineage
cells, also express chemokine receptors [10–12].
Green tea (Camellia sinensis) is one of the most
commonly consumed beverages in the world, with no sig-
nificant adverse side effects [13]. Several epidemiological
and experimental studies using animal models in the
past two decades have verified the antioxidant,
anti-inflammatory and anti-oncogenic properties of the
various polyphenols named catechins found in green tea
[14, 15]. Polyphenol-rich green tea extract (GTE) has
shown inhibitory potential in selectively regulating cell
growth, cell cycle and inducing apoptosis in cancer cells
[16, 17]. Its anti-inflammatory properties were highlighted
when the administration of GTE in drinking water to type II
collagen immunized mice prevented the onset and
severity of arthritis [18]. We recently showed that
epigallocatechin-3-gallate (EGCG), a major constituent of
GTE, inhibits IL-1b-stimulation CC/CXC chemokine pro-
duction and MMP-2 activation in RA synovial fibroblasts
[7]. We also showed recently that EGCG inhibits IL-6
synthesis and transsignalling in human RA synovial fibro-
blasts and rat adjuvant-induced arthritis (AIA) model [19].
The aim of the present study was to decipher the mech-
anism of CC/CXC chemokine regulation and CC/CXC
chemokine receptor expression caused by GTE treatment
in human RA synovial fibroblasts and rat AIA model.
Materials and methods
Antibodies and reagents
GTE was purchased from Sigma-Aldrich (Polyphenon 60
from green tea, Catalogue number P1204; St Louis, MO,
USA). Recombinant IL-1b was purchased from R&D
Systems (Minneapolis, MN, USA). Rabbit polyclonal
antibodies against phosphoprotein kinase C (PKC)d,
total-PKCd, phospho-c-Jun N-terminal kinases (JNK),
total-JNK (Cell Signaling Technology, Beverly, MA, USA)
and b-actin (Sigma-Aldrich, St Louis, MO, USA) were used
in the study. All signalling inhibitors were purchased from
Calbiochem (San Diego, CA, USA) and EMD Chemicals
(Gibbstown, NJ, USA). ELISA kits for RANTES/CCL5,
GROa/CXCL2 and IL-8/CXCL8 were purchased from
R&D Systems (Minneappolis, MN, USA). ELISA kits for
MCP-1/CCL2 were purchased from Invitrogen (Carlsbad,
CA, USA). Rat RANTES/CCL5, GROa/CXCL2 and MCP-1/
CCL2 fluorescence-based Luminex assay kits were pur-
chased from Millipore (Billerica, MA, USA).
Culture of human RA synovial fibroblasts
Fibroblasts were isolated from synovium obtained from
RA patients [20] who had undergone total joint replace-
ment surgery or synovectomy. The study was approved
by the University of Michigan Institutional Review Board.
Fresh synovial tissues were minced and digested in a
solution of dispase, collagenase and DNase [7]. Cells
were used at passage five or older, at which time they
were a homogeneous population. RA synovial fibroblasts
were grown in Roswell Park Memorial Institute (RPMI)
1640 medium supplemented with 10% fetal bovine
serum at 37C in a humidified atmosphere with 5% CO2.
Upon confluence, cells were passaged by brief trypsiniza-
tion, as previously described [7]. All treatments were per-
formed in serum-free medium.
Preparation of GTE solution
A fresh stock solution of GTE (10 mg/ml) was prepared
in water before each study, sterile filtered with 0.2-mm
syringe filters and used in each experiment by adding
directly to the culture medium.
HPLC analysis of GTE
A two-point standard for each catechin was prepared for
calibration using 95% ethanol as diluting solution. Briefly,
100 mg of GTE sample, prepared in duplicate, were
extracted into a 95% ethanol solution using sonication
for 10 min and filtered into HPLC vials. HPLC conditions
were as follows: Octadecyl Silane, 5 mm; column,
250 4.6 mm; flow rate, 1 ml/min; UV-Vis, 274 nm; run
time, 45 min; injecting volume, 5 ml; mobile phase gradient
between acetonitrile and 1% citric acid buffer. HPLC ana-
lysis was performed by Microbac Laboratories (Boulder,
CO, USA).
Cell viability assay
The effect of GTE (10–100 mg/ml) on the viability of RA
synovial fibroblasts (2104/well in 96-well plate) was
studied, as previously described [7], using the MTT
[3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium
bromide]-based cell viability assay according to the
instructions of the manufacturer (Molecular Probes,
Invitrogen, Carlsbad, CA, USA).
Treatment of RA synovial fibroblasts with IL-1b and GTE
To study the effect of GTE on chemokine production, RA
synovial fibroblasts were incubated with or without GTE
(2.5–40mg/ml) in serum-free medium for 12 h, followed
by stimulation with IL-1b (10 ng/ml) for 24 h. After 24 h,
culture supernatants were collected and centrifuged at
10 000 g for 5 min at 4C to remove particulate matter,
and stored at 80C in fresh tubes. Using ELISA kits,
culture supernatants were used to determine the quanti-
ties of MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2 and
IL-8/CXCL8. To study the signalling mechanism of
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chemokine production by IL-1b, RA synovial fibroblasts
were incubated with MAPK inhibitors (ERK½, PD98059;
p38, SB203580; and JNK, SP600125; 10 mM), PKC
inhibitors (general, Ro-318425; PKCa, Gö6976; and
PKCd, Rottlerin; 10mM) or the NFkB inhibitor (PDTC;
200mM) for 2 h, followed by stimulation with IL-1b
(10 ng/ml) for 24 h, and processed for determination of
chemokine production. All inhibitors were purchased
from Calbiochem (San Diego, CA, USA) and the concen-
trations used in this study were based on previous studies
[7, 19].
Induction of arthritis by adjuvant
Female Lewis rats, 100 g (Harlan Laboratories,
Indianapolis, IN, USA), were injected subcutaneously at
the base of the tail with 300 ml (5 mg/ml) of lyophilized
Mycobacterium butyricum (Difco Laboratories, Detroit,
MI, USA) in sterile mineral oil. The day of adjuvant injection
was considered 0 for all time points. Clinical parameters
measured included articular index and ankle circumfer-
ence. Articular index scores were recorded for each hind
joint by a consistent observer blinded to the treatment
regimen and then averaged for each animal. Scoring
was performed on a 0–4 scale where 0 = no swelling or
erythema, 1 = slight swelling and/or erythema, 2 = low to
moderate oedema, 3 = pronounced oedema with limited
joint usage and 4 = excess oedema with joint rigidity.
Ankle circumferences were measured by the same
blinded observer as described previously [21]. The
increase in ankle circumference was presented as delta
() ankle circumference. The  ankle circumferences of
both the hind ankles from each animal were averaged and
‘n’ is represented as the number of animals used in each
of the experimental groups. All animal studies were
approved by the ethics committee of the University of
Michigan.
Treatment of animals with GTE
GTE was brought into suspension in phosphate buffered
saline (PBS). GTE (200 mg/kg) or PBS were administered
daily by oral gavage, with treatment initiated on Day 7
after arthritis induction when the first signs of joint inflam-
mation and pain are usually noted and continued until
Day 16 [9, 22]. On Day 17, animals were anaesthetized
for blood collection by cardiac puncture and then
sacrificed for biochemical and cytokine analysis. For all
comparisons, the PBS group served as a control. A daily
dose of GTE (200 mg/kg) in rats corresponds to one-tenth
of the ‘no observed-adverse-effect level’ dose used earlier
for systemic toxicity study in rats following oral adminis-
tration for 28 days [23].
Assay for rat MCP-1/CCL2, RANTES/CCL5 and
GROa/CXCL2
Ankles used for ELISA were removed, snap frozen and
homogenized on ice using a motorized homogenizer, fol-
lowed by 30 s of sonication in 3 ml of PBS containing
complete Mini protease inhibitor cocktail tablet
(Roche, Indianapolis, IN, USA). Homogenates were
centrifuged at 2500 g for 10 min, filtered through a
0.45-mm pore size filter (Millipore, Billerica, MA, USA)
and stored at 80C until use. Protein concentrations
were measured using a BCA protein assay kit (Pierce
Biotechnology, Rockford, IL, USA). Joint homogenates
were analysed for rat MCP-1/CCL2, RANTES/CCL5 and
GROa/CXCL2 using fluorescence-based Luminex assay
kits (Millipore) according to the manufacturer’s protocol.
The values obtained from the joint homogenates were
normalized to protein content.
Western immunoblotting and analysis
To study the effect of GTE on signalling events, RA
synovial fibroblasts were incubated with or without GTE
(2.5–20mg/ml) in serum-free RPMI 1640 for 12 h,
followed by stimulation with IL-1b (10 ng/ml) for 20 min.
Cells were lysed in cell lysis buffer containing 100 mM
Tris (pH 7.4), 100 mM NaCl, 1 mM ethylenediaminetetra-
acetic acid, 1 mM ethylene glycol tetraacetic acid, 1 mM
NaF, 20 mM NaP2O4, 2 mM Na3VO4, 1% Triton X-100,
10% glycerol, 0.1% SDS, 0.5% deoxycholate, 1 mM phe-
nylmethylsulphonyl fluoride (PMSF) and protease inhibi-
tors (one tablet per 10 ml; Roche, Indianapolis, IN, USA).
Protein was measured using a BCA protein assay kit
(Pierce, Rockford, IL, USA). Equal amounts of protein
(15 mg) were loaded and separated by SDS–PAGE and
transferred onto nitrocellulose membranes (Bio-Rad,
Richmond, CA, USA). Blots were probed using rabbit
polyclonal antibodies specific for phospho-PKCd
isoforms, rabbit monoclonal phopho-JNK and rabbit
polyclonal anti-b-actin. The immunoreactive protein
bands were visualized by enhanced chemiluminescence.
Densitometric analysis of the bands was performed using
UN-SCAN-IT software, version 5.1 (Silk Scientific, Orem,
UT, USA), and the data were analysed using Prism
software (GraphPad Software, San Diego, CA, USA).
RNA extraction and quantitative RT–PCR
Total RNA was isolated from human RA synovial fibro-
blasts and rat ankles using RNAeasy mini RNA isolation
kits in conjunction with QIAshredders (Qiagen, Valencia,
CA, USA) following the manufacturer’s protocol. Following
isolation, RNA was quantified and checked for purity
using a spectrophotometer (Nanodrop Technologies,
Wilmington, DE, USA). cDNA was then prepared using
a Reverse-IT MAX first-strand synthesis kit (Abgene,
Rochester, NY, USA) as per the manufacturer’s protocol.
The primer pairs used were based on published
sequences [24–33] and are summarized in Table 1.
Chemokine and chemokine receptor expression was
measured by real-time RT–PCR in RA synovial fibroblasts
and joints. b-actin was used as a housekeeping gene.
RNA was isolated from RA synovial fibroblasts and rat
joints using RNAeasy mini RNA isolation kits in conjunc-
tion with QIAshredders (Qiagen, Valencia, CA, USA)
according to the manufacturer’s protocol. Following the
isolation, RNA was quantified and checked for purity by
spectrophotometry (Nanodrop Technologies, Wilmington,
DE, USA). cDNA was then prepared using a Reverse-IT
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MAX first-strand synthesis kit, with anchored oligo-DT
RNA primers (Abgene, Rochester, NY, USA) following
the manufacturer’s protocol. Quantitative PCR (qPCR)
was performed using Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s protocol, using specific primer
sequences (Table 1). Diluted cDNA was mixed with
Platinum SYBR Green qPCR SuperMix-UDG, forward
and reverse primers specific for each gene (0.2mM final
concentrations), and incubated at the following cycles:
50C for 2 min, 95C for 2 min and 40 cycles of 95C for
30 s, 55C for 30 s and 68C for 30 s using an Eppendorf
Mastercycler ep realpex thermal cycler (Eppendorf,
Hamburg, Germany). All samples were run in duplicate
and analysed using Eppendorf software. Control reactions
for product identification consisted of analysing the melt-
ing peaks (in degree celsius). A threshold to detect fluo-
rescence above background is determined by the
software. The level of expression of each mRNA and
their estimated crossing points or cycle threshold (Ct)
was determined relative to the standard preparation
using the LightCycler computer software.
Relative gene expression was calculated using Ct
method with b-actin as housekeeping gene
2ðCtbactin CtGeneÞ and the fold increase over mRNA
levels of untreated cells was then determined.
Statistical analysis
Statistical analysis to determine the effect of GTE treat-
ment on RA synovial fibroblasts in vitro for chemokine
production and chemokine receptor expression was
performed using the Kruskall–Wallis one-way analysis of
variance (ANOVA) test, followed by Dunnett’s multiple
comparison post hoc test with P< 0.05 chosen as the
level of significance. Data obtained from rat AIA clinical
measurements, chemokine production and chemokine
receptor expression were analysed using Student’s




HPLC analysis showed that GTE contains 36% (w/w) of
catechins, which included epigallocatechin (EGC, 11.5%),
epicatechin (EC, 8%), epicatechin gallate (8%) and
EGCG (5.9%).
Inhibition of IL-1b-induced RA synovial fibroblast
chemokine production by GTE
IL-1b is a potent inducer of chemokine production in RA
synovial fibroblasts [18]. Excessive production of chemo-
kines by RA synovial fibroblasts has been shown to
induce proliferation of these cells and facilitate invasion
into the adjacent tissues [7]. In the present study, stimu-
lation of RA synovial fibroblasts with IL-1b (10 ng/ml) for
24 h resulted in a 5-, 21-, 21- and 96-fold induction
of MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2 and
IL-8/CXCL8, production, respectively, as compared
with untreated controls (P< 0.05; n5 4). Pretreatment
with GTE caused a significant, but differential, dose-
dependent inhibition of IL-1b-induced MCP-1/CCL2,
RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8 produc-
tion. GTE at 40mg/ml almost completely blocked
IL-1b-induced MCP-1/CCL2, RANTES/CCL5, GROa/
CXCL2 and IL-8/CXCL8 production in RA synovial fibro-
blasts (Fig. 1A–D). MTT assay to assess the viability of RA
synovial fibroblasts showed that GTE (10–100 mg/ml) had
no effect on the viability of cultured RA synovial fibroblasts
at 24 h.
GTE (2.5–40 mg/ml) inhibited IL-1b-induced MCP-1/
CCL2, RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8,
production ranging from 9 to 84%, 36 to 97%, 12 to
99% and 6 to 84%, respectively. Interestingly, the inhibi-
tory concentration 50% (IC50) values for MCP-1/CCL2,
RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8 produc-
tion by GTE were 23.0 (4.2), 6.6 (0.8), 9.1 (1.3) and 13.6
(3.5) mg/ml, respectively.
Table 1 Sequences of the primer pairs used for chemokines and their receptors
Genes Species Forward Reverse
MCP-1/CCL2 Human 50-TCCAGCATGAAAGTCTCTGC-30 50-TGGAATCCTGAACCCACTTC-30
RANTES/CCL5 Human 50-AGCTACTCGGGAGGCTAAGG-30 50-GAGGCATGCTGACTTCCTTC-30
GROa/CXCL2 Human 50-AGGGAATTCACCCCAAGAAC-30 50-CACCAGTGAGCTTCCTCCTC-30
IL-8/CXCL8 Human 50-TTGGCAGCCTTCCTGATT-30 50-AACTTCTCCACAACCCTCTG-30
CCR1 Human 50-ACGGAGGTGATCGCCTACAC-30 50-CGGAACCTGTCACCAACGAA-30
CCR2b Human 50-GCTGGTCCTGCCGCTG-30 50-CACCAAGCAGGGTTTTCA-30
CCR5 Human 50-GGTTGGGGTGGGATAGGG-30 50-TTTAAATGTAGAGGGGGATCCT-30
CXCR1 Human 50-TCCTGGGAAATGACACAGCA-30 50-AAGCCAAAGGTGTGAGGCAG-3 0
CXCR2 Human 50-GGGCAACAATACAGCAAACT-30 50-GCACTTAGGCAGGAGGTCTT-30
CCR1 Rat 50-GGAGTTCACTCACCATACCTGTAG-30 50-GGTCCAGAGGAGGAAGAA-30
CCR2 Rat 50-CGCAGAGTTGACAAGTTGTG-30 50-GCCATGGATGAACTGAGGTA-30
CCR5 Rat 50-CACCCTGTTTCGCTGTAGGAATG-30 50-GCAGTGTGTCATCCCAAGAGTCTC-30
CXCR1 Rat 50-CATCTTCCGCCAGGCATATAAA-30 50-GGGACAGACCACGCAATGTT-30
CXCR2 Rat 50-CAGCAGTGTTCTGTTGCTAGCCT-30 50-CCAAGTGTCTCTTCTGGATCAGTGT-30
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Transcriptional effect of GTE on IL-1b-induced
chemokine production
To further strengthen our understanding of the chemokine
inhibition, we studied the effect of the GTE on
IL-1b-induced chemokine production at the mRNA level.
In the present study, the stimulation of RA synovial
fibroblasts with IL-1b (10 ng/ml) for 24 h resulted in
a 290-, 2000-, 14 000- and 27 000-fold induction
of MCP-1/CCL2, RANTES/CCL5,GROa/CXCL2 and
IL-8/CXCL8 mRNA expression, respectively, as compared
with untreated controls. Surprisingly, treatment with
GTE differentially modulated the IL-1b-induced MCP-1/
CCL2, RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8
mRNA expression (Fig. 2). GTE at 10 mg/ml had
no effect on MCP-1/CCL2, RANTES/CCL5, GROa/
CXCL2 and IL-8/CXCL8 transcription, when compared
with IL-1b-treated values. GTE at 20mg/ml inhibited
MCP-1/CCL2 and GROa/CXCL2 mRNA synthesis by
73% (P< 0.05) and 94% (P< 0.01), respectively. A
trend was observed for RANTES/CCL5 expression,
which was inhibited by 36%. However, GTE at
10 mg/ml induced IL-8/CXCL8 mRNA synthesis (not
significant, NS), whereas GTE at 20 mg/ml had no
inhibitory effect on IL-8/CXCL8 mRNA synthesis. Overall,
the results suggest that GTE possesses an ability to
suppress chemokine production at the transcriptional
level.
Role of PKCd in IL-1b-induced chemokine production
To study the signalling pathways involved in
IL-1b-induced production of chemokines, RA synovial
fibroblasts were pretreated with different signalling inhib-
itors as described in detail in the ‘Materials and methods’
section. The conditioned medium was utilized to estimate
the levels of MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2
and IL-8/CXCL8. The general PKC and the specific PKCd
inhibitors almost completely blocked IL-1b-induced
MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2 and
IL-8/CXCL8 production in RA synovial fibroblasts
(P< 0.001; Fig. 3A–D). In addition, we observed a trend
in the inhibition of RANTES production by SP600125,
a JNK inhibitor (Fig. 3B).
Fig. 1 Inhibition of IL-1b-induced production of MCP-1/CCL2 (A), RANTES/CCL5 (B), GROa/CXCL2 (C) and IL-8/CXCL8
(D) by GTE in RA synovial fibroblasts.
RA synovial fibroblasts (2104/well) were incubated with GTE (0–40mg/ml) for 12 h, followed by stimulation with IL-1b
(10 ng/ml) for 24 h. The production of MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8 in culture super-
natants was measured using a commercially available ELISA kit. The values were mean and SEM. n: number of RA
synovial fibroblast donors used.
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Modulation of PKCd signalling pathways by GTE to
inhibit IL-1b-induced chemokine production
In light of these observations, we evaluated the effect
of GTE treatment on IL-1b-induced phosphorylation of
PKCd and JNK (Fig. 4A and B). Densitometric analysis
of protein bands showed that IL-1b (10 ng/ml) increased
phospho-PKCd to almost 2-fold as compared with the
untreated samples (P< 0.05; Fig. 4A). Treatment of
RA synovial fibroblasts with GTE (2.5–20 mg/ml) caused a
dose-dependent inhibition in the expression of
phospho-PKCd ranging from 43 to 73% (P< 0.05 for
GTE 5, 10 and 20 mg/ml; Fig. 4A). Similarly, IL-1b
(10 ng/ml) increased the expression of phospho-JNKp46
and -p54 to almost 3-fold as compared with the
untreated samples (P< 0.05 for phospho-JNKp54;
Fig. 4B). Normalization of the phosphorylated p46 and
p54 isoforms of JNK with their respective total p46 and
p54 protein levels showed that GTE had no significant
inhibitory effect on any of the JNK isoforms as compared
with IL-1b-treated levels (Fig. 4B). These results provide
evidence that GTE may regulate chemokine production
predominantly via the PKCd pathway in RA synovial
fibroblasts.
Fig. 3 Involvement of PKCd in the regulation of IL-1b-induced chemokine production.
RA synovial fibroblasts (2105/well) were pretreated with MAPK inhibitors (ERK½, PD98059; p38, SB203580; and JNK,
SP600125; 10 mM), PKC inhibitors (general, Ro-318425; PKCa, Gö6976; and PKCd, Rottlerin; 10 mM) and NF-kB inhibitor
(PDTC; 200mM) for 2 h, followed by stimulation with IL-1b (10 ng/ml) for 24 h and processed for estimation of MCP-1/
CCL2 (A), RANTES/CCL5 (B), GROa/CXCL2 (C) and IL-8/CXCL8 (D) production. Values are mean and SEM. *P< 0.05 vs
treatment with IL-1b alone. n: number of RA synovial fibroblast donors used.
Fig. 2 Modulation of IL-1b-induced MCP-1/CCL2,
RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8
expression by GTE in RA synovial fibroblasts.
RA synovial fibroblasts (2 105/well) were incubated with
GTE (10–20mg/ml) for 12 h, followed by stimulation with
IL-1b (10 ng/ml) for 24 h. The mRNA expression of MCP-1/
CCL2, RANTES/CCL5, GROa/CXCL2 and IL-8/CXCL8
was analysed by qRT–PCR. The values were normalized
to their respective b-actin mRNA levels and expressed as
mean and SEM. *P< 0.05 vs treatment with IL-1b alone.
n: number of RA synovial fibroblast donors used.
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GTE-induced chemokine receptor expression in vitro
Since chemokines execute their detrimental effects via
their respective chemokine receptors, we extended our
study and tested the effect of GTE on constitutive and
induced CC/CXC receptor expression by qRT–PCR. RA
synovial fibroblasts were pre-incubated with GTE (10 and
20 mg/ml) for 12 h, followed by stimulation with or without
IL-1b (10 ng/ml) for 24 h. The qRT–PCR analysis showed
that GTE was able to induce CCR1, CCR2b, CCR5,
CXCR1 and CXCR2 dose-dependent expression (n55;
P< 0.05 for CCR2b, -5, CXCR1 and -2 at 20 mg/ml).
Fig. 4 Inhibition of IL-1b-induced PKCd phosphorylation by GTE in RA synovial fibroblasts.
RA synovial fibroblasts (2105/well) were treated with GTE (2.5–20 mg/ml) for 12 h, followed by stimulation with IL-1b
(10 ng/ml) for 20 min. Cells were lysed in extraction buffer containing protease inhibitors, and the total and phosphory-
lated (p) PKCd (A) and JNK (B) were determined by western blotting. A representative blot for each protein is shown.
Equal loading of protein was verified by re-probing the blots for b-actin. Values are mean and SEM of RA synovial
fibroblasts obtained from six different donors. *P< 0.05 vs treatment with IL-1b. OD: optical density; n: number of RA
synovial fibroblast donors used.
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IL-1b had no significant effect on any of the RA synovial
fibroblast CCR or CXCR expression, whereas GTE
pre-incubation further enhanced the IL-1b-induced
expression of these chemokine receptors. These results
suggest that GTE, by enhancing receptor expression,
may enhance the binding of CC/CXC chemokines
to their receptors, thereby reducing the amounts
of these chemokines available to induce chemotaxis
(Fig. 5A).
PKCd inhibitor mimics GTE in increasing chemokine
receptor expression
To further validate the utility of GTE-mediated increase in
CC/CXC receptor expression, we tested the effect of the
Fig. 5 Enhancement of IL-1b-induced CCR1, CCR2b, CCR5, CXCR1 and CXCR2 mRNA expression by GTE in RA
synovial fibroblasts.
(A) RA synovial fibroblasts (2 105/well) were incubated with or without GTE (10–20 mg/ml) for 12 h, followed by stimu-
lation with IL-1b (10 ng/ml) for 24 h. The mRNA expression of CCR1, CCR2b, CCR5, CXCR1 and CXCR2 was analysed by
qRT–PCR. (B) RA synovial fibroblasts (2 105/well) were incubated with or without Rottlerin (10 mM) for 25 h. (C) RA
synovial fibroblasts (2105/well) were incubated with or without Rottlerin (10 mM) for 1 h, followed by stimulation with
IL-1b (10 ng/ml) for 24 h. The mRNA expression of CCR1, CCR2b, CCR5, CXCR1 and CXCR2 was analysed by qRT–PCR.
The values were normalized to the respective b-actin mRNA levels and expressed as mean and SEM. *P< 0.05 vs
treatment with IL-1b alone. n: number of RA synovial fibroblast donors used.
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PKCd inhibitor on constitutive and IL-1b-induced CC/CXC
chemokine receptor mRNA expression. The qRT–PCR
analysis showed that PKCd blockade enhanced CC/CXC
receptor expression by 2-fold as compared with
untreated levels (NS; Fig. 5B). We also observed 5-fold
further synergistic induction in CC/CXC receptor expres-
sion by the PKCd inhibitor when cells were treated with
IL-1b (P< 0.05 for CCR1, CCR2b, CXCR1 and CXCR2;
Fig. 5C). These results suggest that GTE might be mediat-
ing its effect on CC/CXC receptors via modulation of
these signalling pathways.
GTE administration ameliorates rat AIA
We utilized a rat AIA model in which chemokine produc-
tion and chemokine receptor expression peaks in the
arthritic joints around Day 18, which coincides with
maximum inflammation and joint destruction [19, 34].
To study in vivo modulation of CC/CXC chemokines by
GTE in rats, a daily dose (200 mg/kg/oral gavage) was
administered starting from Day 7 to 16. Interestingly, the
evaluation of RANTES/CCL5, MCP-1/CCL2 and
GROa/CXCL2 levels in the joint homogenates of animal
sacrificed at Day 17 showed that GTE treatment signifi-
cantly inhibited MCP-1/CCL2 and GROa/CXCL2 levels by
almost 64 and 78%, respectively (P< 0.05 for both),
with no change in the level of RANTES/CCL5, when com-
pared with the PBS group (Fig. 6A). However, the qRT–
PCR analysis showed that GTE administration was able to
induce CCR1, CCR2b, CCR5 and CXCR1 expression in
the ankles of the GTE administered group compared with
the PBS group (Fig. 6B).
In GTE-fed animals, we also observed a reduction in the
clinical measurements of joint inflammation and arthritis
(Fig. 7A–C). The articular index and the  circumference
of the ankles in GTE administered rats was 28%
(P = 0.212) and 38% (P = 0.187) lower, respectively,
than the PBS group at Day 17 (Fig. 7A and B) by
Day 17. The level of significance (P< 0.05) could not be
achieved in this experiment, which may be attributed to
several contributing factors including the late start of the
dosing regimen, the number of animals (n) in the study and
the day of termination of the study for evaluation.
Nonetheless, the present study clearly suggests that
consumption of GTE during the development of AIA in
rats was able to retard the course of the disease in
GTE-administered rats when compared with the PBS
group. Importantly, the trend of CCR and CXCR receptor
expression in human RA synovial fibroblasts was similar
to that observed in rat AIA, suggesting a potential mech-
anism by which GTE may suppress inflammation and joint
destruction in RA. In addition, GTE (200 mg/kg) adminis-
tration showed no adverse effect on the body weight gain
of the treated animals (Fig. 7C). Overall, these results sug-
gest that GTE ameliorates rat AIA by preferentially
down-regulating the concentrations of chemokines and
enhancing the expression of chemokine receptors in the
joints.
Discussion
In the present study, we provide evidence of the ability of
GTE to differentially regulate chemokine production and
chemokine receptor expression in human RA synovial
fibroblasts and rat AIA. These results suggest that GTE
may play an important role in modifying the responses
of RA synovial fibroblasts towards stimuli generated by
cytokines and chemokines.
CC/CXC chemokines are elevated in RA SFs when
compared with the other joint disorders [35, 36]. MCP-1/
CCL2 and RANTES/CCL5 are the members of the CC
subfamily and have been shown to chemoattract lympho-
cytes and monocytes [37], whereas GROa/CXCL2 and
IL-8/CXCL8 are the members of the CXC chemokine
Fig. 6 GTE administration suppresses chemokine
production, but up-regulates chemokine receptor mRNA
expression, in rat AIA joints.
(A) MCP-1/CCL2, RANTES/CCL5 and GROa/CXCL2
levels in joint homogenates were determined by ELISA.
Values represent the mean ± SEM of the chemokine con-
centration in the joints from eight or seven rats after nor-
malization to their respective protein values. (B) The
mRNA expression of CCR1, CCR2b, CCR5 and CXCR1
was analysed in rat joints from GTE- or PBS-administered
groups. The values were normalized to the respective
b-actin mRNA levels. Values shown are mean ± SEM of
the joints from eight rats (PBS group) or seven rats (GTE
group).
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sub-group that possess both potent chemoattractant and
neutrophil activation functions [8, 38]. These chemokines
are produced by RA synovial fibroblasts and
are up-regulated upon stimulation with IL-1b [7, 39–41].
In animal models of arthritis, the expression of these
chemokines generally coincides with the onset of clinical
symptoms [42–45], and we targeted this by GTE adminis-
tration. In the present study, GTE significantly inhibited
the expression of MCP-1/CCL2 and GROa/CXCL2
in rat AIA. Additionally, GTE blocked IL-1b-induced
MCP-1/CCL2, RANTES/CCL5, GROa/CXCL2 and IL-8/
CXCL8 production by RA synovial fibroblasts in a
concentration-dependent manner. When we explored
the effect of GTE at mRNA level in RA synovial fibroblasts,
we observed a paradoxical effect of GTE on IL-8/CXCL8
expression. Previously, GTE was described to specifically
inhibit IL-8/CXCL8 secretion while inducing de novo syn-
thesis of IL-8/CXCL8 in a human gastrointestinal cell line
[46], suggesting differences in its regulation between tran-
scription and translation events. A similar mechanism
could explain the fact that in RA synovial fibroblasts,
GTE decreased IL-8/CXCL8 production in culture
supernatants, but not at the mRNA level.
In the present study, we confirmed at the mRNA level
that CC/CXC receptors were not restricted to T cells, but
were also expressed by RA synovial fibroblasts as pre-
viously described by PCR and flow cytometry [47, 48].
However, previous data supported the notion that chemo-
kine receptors expressed by RA synovial fibroblasts are
very stable despite stimulation with TNF-a, IL-1b and
IFN-g over 24 h [47]. In addition, our data show that
IL-1b (10 ng/ml) is also capable of modestly inducing
CCR5 and CXCR2. In the light of the present findings,
there are two potential mechanisms that could be
suggested for these unique differential effects induced
by GTE. First, by inhibiting chemokine synthesis, GTE
directly reduces the chemokine pool available for
CC/CXC receptor binding. Secondly, by increasing
chemokine receptor expression, GTE maximizes chemo-
kine ligand–receptor binding that consequently reduces
the amount of free chemokine available for binding to
leucocytes or monocytes/macrophages, thus acting as a
chemokine trap and reducing the chemotactic environ-
ment [1]. However, this explanation warrants further test-
ing of the effect of GTE on other cell types that are present
in the joint that may contribute to chemotactic activity
and angiogenesis [1, 28].
Furthermore, we observed that GTE reduced
IL-1b-induced chemokine production at 24 h, which is
largely attributed to the decreased expression of chemo-
kines relevant to RA [1]. In the present study, GTE also
blocked IL-1b-induced phosphorylation of PKCd. We
extended our previous observation demonstrating that
the regulation of PKCd plays an important role in control-
ling IL-1b-induced chemokine production and chemokine
receptor expression in RA synovial fibroblasts [7], and that
GTE possesses the ability to control their expression by
targeting the PKCd pathway in RA synovial fibroblasts.
However, RANTES production was also reduced by a
Fig. 7 GTE ameliorates AIA in rats.
(A and B) GTE (200 mg/kg/day, p.o.) was administered
daily from Day 7 to 16. Articular index scores were aver-
aged for each animal and  ankle circumferences (minus
Day 0) values were averaged for each animal before group
comparisons and final values represented as the mean of
‘n’ number of animals per group. Mean ± SEM is shown for
ankle articular index scores (range 0–4) and ankle 
circumferences (in millimetres) determined on indicated
days after adjuvant injection. (C) The mean ± SEM
increases in body weight measured on the indicated days
after adjuvant injection. n: number of animals used for
the clinical assessment. Details are provided in the
‘Materials and methods’ section.
476 www.rheumatology.oxfordjournals.org











JNK inhibitor, which may suggest complexity of the invol-
vement of multiple pathways in chemokine regulation.
Data from animal models suggest that blockade of che-
mokine receptors may suppress arthritis by inhibiting neu-
trophil migration to inflamed joints [49]. However, the
acceleration of arthritis in chemokine receptor knockout
animals suggests their regulatory role in the development
of arthritis, which warrants further investigation [50].
The concentration of GTE used to inhibit chemokine
production and chemokine receptor expression may be
achieved by consuming GTE as a dietary supplement
and may possibly have a preventative effect in regulating
the course and clinical outcomes of RA in humans. On this
line of investigation, it will be interesting to suggest future
studies to evaluate the influence of dietary consumption of
GTE on first-line conventional treatment options for RA
such as MTX or other DMARDs for the possible better
clinical outcome in animal models of arthritis. Further stu-
dies may be designed to improve the clinical outcome
in animal models of RA through modification of the
dose, and frequency of GTE administration may provide
a better outcome and benefits of GTE in RA. In conclu-
sion, the novel findings of this study are that GTE inhibits
CC/CXC chemokine production, but up-regulates
CC/CXCR chemokine receptor expression, in both RA
synovial fibroblasts and rat AIA. Hence, it is suggested
that the prophylactic use of GTE alone or as an adjunct
treatment for human RA may be a beneficial therapeutic
approach.
Rheumatology key messages
. Dietary consumption of green tea may be beneficial
in reducing inflammation in RA.
. Complimentary/alternative therapies may be helpful
in regulating chemokine activity in RA.
. As a natural product, these findings for green tea
have the potential for a rapid clinical impact.
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